A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir

Koji Fukushima, Yoshiyuki Ueno, Jun Inoue, Yuta Wakui, Noriyuki Obara, Osamu Kimura, Osamu Kido, Yu Nakagome, Eiji Kakazu, Yasunori Matsuda, Takayuki Kogure, Yasuteru Kondo, Futoshi Nagasaki, Yoko Yamagiwa, Yugo Ashino, Tooru Shimosegawa

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


We report a case of a HIV and hepatitis B virus (HBV)-co-infected patient to whom entecavir (ETV) was administered initially before the notification regarding the potential mutagenesis effect on HIV against the nucleoside analog. Since initial evaluations indicated the advanced stage of chronic hepatitis B and preserved numbers of peripheral CD4+ lymphocytes without the manifestation of immunodeficiency, priority was given to the management of HBV. We started HBV therapy with ETV at a dose of 0.5mg daily without using any HIV drugs. The viral loads of both HBV and HIV-1 decreased gradually during the 5 months following the initial administration of ETV. HBV was well controlled by the gradual replacement of ETV with highly-active antiretroviral therapy against HIV with a regimen including atazanavir, emtricitabine, and tenofovir. HBV was genotyped as A2 with the quasispecies pool consisting of the -1G precore/core deletion mutant strain.

Original languageEnglish
Pages (from-to)842-846
Number of pages5
JournalHepatology Research
Issue number8
Publication statusPublished - 2008 Aug


  • Co-infection
  • Entecavir
  • HIV
  • Hepatitis B virus

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases


Dive into the research topics of 'A case of HIV co-infected with hepatitis B virus precore/core deletion mutant treated by entecavir'. Together they form a unique fingerprint.

Cite this